Solid Tumor Program Clinical Studies

11 - 15 of 15

Lutathera in Somatostatin Neuroendocrine Tumors

This study involves taking a study drug called Lutathera. The overall goal of this study is to see if Lutathera is safe in adolescent subjects with either a gastroenteropancreatic neuroendocrine tumor (GEP-NET), or a pheochromocytoma and/or paraganglioma (PPGL). This study will also look at the levels of radioactivity after Lutathera administration.

BA3011 for advanced solid tumors

This study involves taking a study drug called BA3011. The overall goal of this study is to see if BA3011 is a possible treatment for patients with sarcoma.

ON-TRK

The goal of this observational study is to describe the safety and effectiveness of larotrectinib in patients with locally advanced or metastatic TRK fusion cancer for whom a decision to treat with larotrectinib has been made before enrollment.
This study will enroll participants with any tumors harboring the NTRK gene fusion including Soft Tissue Sarcomas, Central Nervous System, Melanoma, and Thyroid cancers.

Lurbinectedin in Ewing Sarcoma

This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of lurbinectedin are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing Sarcoma.

Synovial Sarcoma Registry / Biospecimen Repository

This study enrolls patients of any age with a diagnosis of synovial sarcoma. The purpose of this study is to establish a registry and biorepository for synovial sarcoma patients by collecting and storing data and biospecimens, such as blood, saliva and/or buccal (cheek) swabs, and tumor tissue. 
If you or your child are interested in participating in this study, please click on this REDCap Survey to complete a study interest form. A study investigator will contact you to discuss the study in more detail. 
11 - 15 of 15

Pages